Docket No: 09425/46702 Serial No: 09/854,568

Response with RCE to final Office Action

## Amendments to the Claims:

Please amend the claims as follows. The following listing should replace all previous listings of the claims.

- 1. (Currently amended) A process method for killing glioma cancer cells in a subject wherein said glioma cancer cells express malignin for stimulating the immune system of a subject to produce and release antimalignin antibody, said process said method said method comprising administering to the said subject an effective amount of a first dosage of a composition comprising malignin wherein said malignin is derived from glioblastoma brain tumor cells and wherein said administration of said dosage stimulates the immune system of said subject to produce and release antimalignin antibody that binds said glioma cancer cells and is cytotoxic to said glioma cancer cells to kill said glioma cancer cells, recognin M, Recognin L or a peptide having the immunological specificity thereof, which process does not by itself protect against or treat cancer.
- 2. (Original) The process of claim 1 wherein the composition is administered as an approximately 1 mg dosage form.
- 3. (Original) The method of claim 1 further comprising administering a second dose of the composition ten days after administration of the first dosage.
- 4. (Original) The method of claim 3 further comprising administering a third dose of the composition ten days after administration of the second dosage.
- 5. (Currently amended) A composition for killing glioma cancer cells in a subject wherein said glioma cancer cells express malignin and wherein administration of an effective amount of a dosage of said composition stimulates the immune system of a subject to produce and release antimalignin antibody that binds said glioma cancer cells and is cytotoxic to said glioma cancer cells, said composition comprising malignin derived from glioblastoma brain tumor cells, recognin M, recognin L or a peptide having the

Docket No: 09425/46702

Serial No: 09/854,568 Response with RCE to final Office Action

immunological specificity thereof, wherein said stimulating the immune system does not by itself protect against or treat cancer.

- 6. (Withdrawn) An antimalignin antibody.
- 7. (Withdrawn) A device for removing cancer cells from the body of a subject, said device comprising cells having immunological specificity for malignin, recognin L or recognin M, wherein said device binds, absorbs or engulfs cancer cells which come into contact therewith.
- 8. (Withdrawn) The device of claim 7 wherein said device comprises a filter through which the cancer cells are passed.
- 9. (Withdrawn) The device of claim 7 wherein the device comprises a surface over which the cancer cells are passed.
- 10. (Withdrawn) The device of claim 7 wherein the device comprises a resin over which the cancer cells are passed.
- 11. (Withdrawn) The device of claim 7 wherein the cells are selected from the group consisting of T cells, B cells and phagocytes.
- 12. (Withdrawn) A process for ascertaining the presence of cells transformed to the malignant state in a subject
  - (1) obtaining a fluid or tissue specimen from the subject;
  - quantifying the amounts of antimalignin antibody and/or immune cells having specificity for malignin, recognin L and/or recognin M in the fluid or tissue specimen;
  - (3) correlating the amounts to the presence of cells transformed to the malignant state.

4

Docket No: 09425/46702

Serial No: 09/854,568

Response with RCE to final Office Action

13. (Withdrawn) An antimalignin antibody having a cytotoxic agent attached thereto.

5